Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS

NCT00666497 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT00666497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00666497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2008
Completion date
April 30, 2009
Enrollment
6 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), myelodysplastic syndrome (mds)